Skip to main content

Table 1 Summary of patient and tumor characteristics

From: The tumor immune microenvironment of primary and metastatic HER2− positive breast cancers utilizing gene expression and spatial proteomic profiling

Patient Tissue Diagnosis ER(%)/PR(%)/HER2( +) PAM50 Subtype TIS Status Treatment at the time of sample collection
1 Breast IDC, DCIS 2/0/3 Luminal A High Gemcitabine and trastuzumab
1 Breast Tumor emboli N/A Luminal A High Nab-paclitaxel and trastuzumab
1 Lung Metastatic 0/0/3 HER2 enriched High Nab-paclitaxel and trastuzumab
2 Breast ICD, DCIS 0/0/3 HER2 enriched Low None. Initial diagnosis
2 Breast Residual IDC 0/0/N/A HER2 enriched High TDM1, pertuzumab, doxorubicin and cyclophosphamide*
2 Soft tissue Local recurrence 0/0/3 HER2 enriched Low Trastuzumab and pertuzumab
3 Brain Metastatic 15/0/3 HER2 enriched Low None. Discontinued due to toxicities
4 Breast IDC 0/0/3 Basal like High None. Initial diagnosis
4 Breast Local recurrence N/A Luminal A High Doxorubicin, cyclophosphamide, paclitaxel and trastuzumab
5 Brain Metastatic 0/0/3 Basal like Low TDM1 and anastrozole
6 Breast IDC, DCIS 80/70/2** Luminal A High None. Initial diagnosis
7 Breast IDC, DCIS 0/0/3 HER2 enriched High None. Initial diagnosis
7 Breast Local recurrence N/A Basal like High None. Completed neoadjuvant and adjuvant therapy
8 Breast IDC, DCIS 10/15/1 Luminal A Low None. Initial diagnosis
8 Soft tissue Local recurrence 0/0/3 Basal like Low Nab-paclitaxel and atezolizumab (previously had triple negative disease)
  1. DCIS: ductal carcinoma in situ; DCIS: ductal carcinoma in situ; ER: estrogen receptor; HER2: human epidermal growth factor 2; IDC: invasive ductal carcinoma; IDC: invasive ductal carcinoma; PR: progesterone receptor; TDM1: ado-trastuzumab emtansine; TIS: tumor inflammation score
  2. *Neoadjuvant therapy in the ISPY2 clinical trial
  3. **HER2/CEP17 ratio: 2.13 (amplified by FISH)